Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Mar:58:101013.
doi: 10.1016/j.blre.2022.101013. Epub 2022 Sep 6.

Management of infection in PNH patients treated with eculizumab or other complement inhibitors: Unmet clinical needs

Corrado Girmenia  1 , Wilma Barcellini  2 , Paola Bianchi  2 , Eros Di Bona  3 , Anna Paola Iori  4 , Rosario Notaro  5 , Simona Sica  6 , Alberto Zanella  2 , Antonio De Vivo  7 , Giovanni Barosi  8 , Antonio Risitano  9 ; scientific committee of the Associazione Italiana Emoglobinuria Parossistica Notturna (AIEPN)
Affiliations
Review

Management of infection in PNH patients treated with eculizumab or other complement inhibitors: Unmet clinical needs

Corrado Girmenia et al. Blood Rev. 2023 Mar.

Abstract

This article presents the results of group discussion among an ad hoc constituted panel of experts aimed at identifying and addressing unmet clinical needs (UCNs) in the management of infectious risk associated with eculizumab or new terminal complement inhibitors (CIs) in paroxysmal nocturnal hemoglobinuria (PNH). With the Delphi technique, the most clinically relevant UCNs in PNH patients candidate to or on terminal CI were selected. They resulted to be: optimizing the infection prevention measures; developing non pharmacological infectious risk-mitigation strategies; improving the management of disease exacerbation during infectious complications. For each of these issues consensus opinions were provided and, when appropriate, proposals for advancement in clinical practice were addressed. The hope is that this comprehensive overview will serve to improve the practice of CIs therapy and inform the design and implementation of new studies in the field.

Keywords: Chemoprophylaxis; Complement inhibitors; Eculizumab; Infections; Paroxysmal nocturnal hemoglobinuria; Vaccination.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest C. Girmenia has received honoraria from Gilead Sciences, MSD, Pfizer Pharmaceuticals, Celgene, Novartis, Janssen, Takeda, Amgen, GSK, Biotest and Alexion Pharmaceuticals. W. Barcellini has received honoraria from Agios, Alexion, Apellis, Biocryst, Incyte, Janssen, Momenta, Novartis, Sanofi, SOBI and Alexion Pharmaceuticals. P. Bianchi has received honoraria from Agios Pharmaceuticals, Rocket Pharmaceuticals and Alexion Pharmaceuticals. E. Di Bona has received honoraria from Alexion Pharmaceuticals a. A.P. Iori has received honoraria from Novartis, Takeda, Amgen, JAZZ and Alexion Pharmaceuticals. R. Notaro has received honoraria from BioCryst, SOBI Pharmaceuticals and Alexion Pharmaceuticals. S. Sica: has received honoraria from Amgen Jazz, Pfizer, Astellas, Sobi and Alexion Pharmaceuticals. A. Zanella has received honoraria from Agios e Rocket Pharma. and Alexion Pharmaceuticals. A. De Vivo has received honoraria from Takeda Italia, Sobi Italia and Alexion Pharmaceuticals. G.Barosi has received honoraria from Alexion Pharmaceuticals. A. Risitano has received honoraria from Apellis, Sobi, Novartis, Roche, Samsung, Pfizer and Alexion Pharmaceuticals.

Publication types

MeSH terms

Substances

LinkOut - more resources